Skip Navigation


Annals of Oncology Advance Access originally published online on June 9, 2006
Annals of Oncology 2006 17(8):1205-1212; doi:10.1093/annonc/mdl135
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
17/8/1205    most recent
mdl135v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (14)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Martín, M.
Right arrow Articles by Mel, J. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Martín, M.
Right arrow Articles by Mel, J. R.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2006 European Society for Medical Oncology

Toxicity and health-related quality of life in breast cancer patients receiving adjuvant docetaxel, doxorubicin, cyclophosphamide (TAC) or 5-fluorouracil, doxorubicin and cyclophosphamide (FAC): impact of adding primary prophylactic granulocyte-colony stimulating factor to the TAC regimen

M. Martín1,*, A. Lluch2, M. A. Seguí3, A. Ruiz4, M. Ramos5, E. Adrover6, Á. Rodríguez-Lescure7, R. Grosse8, L. Calvo9, C. Fernandez-Chacón10, M. Roset11, A. Antón12, D. Isla13, P. Martínez del Prado14, L. Iglesias15, J. Zaluski16, A. Arcusa17, J. M. López-Vega18, M. Muñoz19 and J. R. Mel20

1 Hospital Universitario San Carlos, Madrid, Spain; 2 H. Clínico Universitario de Valencia, Valencia, Spain; 3 Corporación Sanitaria Parc Taulí, Sabadell, Spain; 4 Instituto Valenciano de Oncología, Valencia, Spain; 5 Centro Oncolígico de Galicia, La Coruña, Spain; 6 H. General Universitario de Alicante, Alicante, Spain; 7 H. General Universitario de Elche, Elche, Spain; 8 Klinik und Poliklinik Gynäkologie, Halle, Germany; 9 C.H. Universitario Juan Canalejo, La Coruña, Spain; 10 PIVOTAL, Madrid, Spain; 11 HORE, Barcelona, Spain; 12 H. Universitario Miguel Servet, Zaragoza, Spain; 13 H. Clínico Universitario Lozano Blesa, Zaragoza, Spain; 14 H. De Basurto, Bilbao, Spain; 15 H. Universitario Virgen del Rocío, Sevilla, Spain; 16 Wielkopolskie Centrum Onkologii, Poznan, Poland; 17 H. de Terrassa, Terrasa, Spain; 18 H. Universitario Marqués de Valdecilla, Santander, Spain; 19 H. Clinic i Provincial, Barcelona, Spain; 20 C. H. Xeral-Calde, Lugo, Spain

* Correspondence to: Dr M. Martin, Servicio de Oncologia Medica, Hospital Universitario San Carlos, Spain. Tel: +34-91-3303546; Fax: +34-91-5436223; E-mail: mmartin{at}geicam.org

Background: The aim of the study was to analyse the toxicity and health related quality of life (HRQoL) of breast cancer patients treated with FAC (5-fluorouracil, doxorubicin, cyclophosphamide) and TAC (docetaxel, doxorubicin, cyclophosphamide) with and without primary prophylactic G-CSF (PPG).

Patients and methods: This was a phase III study to compare FAC and TAC as adjuvant treatment of high-risk node-negative breast cancer patients. After the entry of the first 237 patients, the protocol was amended to include PPG in the TAC arm due to the high incidence of febrile neutropenia. A total of 1047 evaluable patients from 49 centres in Spain, two in Poland and four in Germany were included in the trial. Side-effects and the scores of the EORTC QLQ-C30 and QLQ BR-23 questionnaires were compared in the three groups (FAC, TAC pre-amendment and TAC post-amendment).

Results: The addition of PPG to TAC significantly reduced the incidence of neutropenic fever, grade 2–4 anaemia, asthenia, anorexia, nail disorders, stomatitis, myalgia and dysgeusia. Patient QoL decreased during chemotherapy, more with TAC than FAC, but returned to baseline values afterwards. The addition of PPG to TAC significantly reduced the percentage of patients with clinically relevant Global Health Status deterioration (10 or more points over baseline value) at the end of chemotherapy (64% versus 46%, P < 0.03).

Conclusions: The addition of PPG significantly reduces the incidence of neutropenic fever associated with TAC chemotherapy as well as that of some TAC-induced haematological and extrahaematological side-effects. The HRQoL of patients treated with TAC is worse than that of those treated with FAC but improves with the addition of PPG, particularly in the final part of chemotherapy treatment.

Key words: adjuvant chemotherapy, docetaxel, TAC, G-CSF, filgrastim, lenograstim, operable breast cancer


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Am J Health Syst PharmHome page
E. J. Ip, A. Lee-Ma, L. S. Troxell, and J. Chan
Low-dose filgrastim in patients with breast cancer treated with docetaxel, doxorubicin, and cyclophosphamide
Am. J. Health Syst. Pharm., August 15, 2008; 65(16): 1552 - 1555.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
S. E. Wolowacz, D. A. Cameron, H. C. Tate, and A. Bagust
Docetaxel in Combination With Doxorubicin and Cyclophosphamide As Adjuvant Treatment for Early Node-Positive Breast Cancer: A Cost-Effectiveness and Cost-Utility Analysis
J. Clin. Oncol., February 20, 2008; 26(6): 925 - 933.
[Abstract] [Full Text] [PDF]

Home page
 Journal of Pharmacy PracticeHome page
L.-P. P. Tran and J. L. Grabinski
Chemotherapy for Early-Stage Breast Cancer: A Paradigm in Flux
Journal of Pharmacy Practice, February 1, 2008; 21(1): 46 - 56.
[Abstract] [PDF]

Home page
 Ann OncolHome page
G. von Minckwitz, S. Kummel, A. du Bois, W. Eiermann, H. Eidtmann, B. Gerber, J. Hilfrich, J. Huober, S. D. Costa, C. Jackisch, et al.
Pegfilgrastim {+/-} ciprofloxacin for primary prophylaxis with TAC (docetaxel/doxorubicin/cyclophosphamide) chemotherapy for breast cancer. Results from the GEPARTRIO study
Ann. Onc., February 1, 2008; 19(2): 292 - 298.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
J Alexandre, E Rey, V Girre, S Grabar, A Tran, V Montheil, F Rabillon, V Dieras, V Jullien, P Herait, et al.
Relationship between cytochrome 3A activity, inflammatory status and the risk of docetaxel-induced febrile neutropenia: a prospective study
Ann. Onc., January 1, 2007; 18(1): 168 - 172.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
P. S. Hupperets and V. C. Tjan-Heijnen
Primary or secondary G-CSF prophylaxis to support TAC chemotherapy in breast cancer?
Ann. Onc., August 1, 2006; 17(8): 1181 - 1183.
[Full Text] [PDF]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.